Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-21

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer.

The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases circulating levels of SHBG more than lifestyle intervention (LI) with or without intermittent caloric restriction (ICR) after 6 months in women at increased risk of breast cancer (i.e., healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or with \> 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models or with a recently resected intraepithelial neoplasia of the breast (IEN).

The secondary aims are:

* to verify whether ICR significantly modulates primary and secondary endpoints such as Homeostasis Model Assessment (HOMA) index, immune and inflammatory markers, lipid profile, Adiponectin/Leptin (A/L) ratio, quality of life (QoL), Body mass index (BMI), fat body composition, safety and toxicity;
* to verify whether LDT significantly modulates secondary endpoints, such as HOMA-index, immune and inflammatory markers, lipid profile, A/L ratio, QoL, BMI, fat body composition, safety and toxicity;
* to investigate differences in microbiome composition by arms and the effect of changes in microbiome on QoL taking into account circulating biomarkers, cytokines, immune modulators, and inflammatory proteins in serum;
* to investigate MD (Mammographic Breast Density) changes by LDT vs. LI, with or without ICR. This aim will be performed in a subgroup of participants (not all the participants will undergo mammography due to younger age).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE2

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973

Breast Neoplasms Tamoxifen

COMPLETED

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

NCT01357772

Carcinoma, Intraductal, Noninfiltrating Recurrence, Local Neoplasm Breast Neoplasms +1 more

ACTIVE_NOT_RECRUITING PHASE3

Tamoxifen in Treating Women With Breast Cancer

NCT00003678

Breast Cancer

UNKNOWN PHASE3

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369

Breast Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Italian, multicenter, phase II, biomarker trial. A total of 200 women aged 18-70 years will be randomly assigned (1:1:1:1) to one of the four intervention arms Arm 1: Low dose Tamoxifen (LDT) i.e. 10 mg every other day; Arm 2: Low dose Tamoxifen (LDT) + Intermittent Caloric Restriction (ICR); Arm 3: Lifestyle intervention (LI) using a step counter; Arm 4: Lifestyle intervention (LI) using a step counter + Intermittent Caloric Restriction (ICR).

Participants will be stratified by center and by disease status (high risk vs. previous IEN) and intervention will last six months for all arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

BRCA Mutation PALB2 Gene Mutation Ductal Carcinoma in Situ Lobular Carcinoma in Situ ATM Gene Mutation CHEK2 Gene Mutation CDH1 Gene Mutation RAD51C Gene Mutation RAD51D Gene Mutation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose tamoxifen

Tamoxifen 10 mg (1 tablet) every other day for 6 months.

Group Type ACTIVE_COMPARATOR

Tamoxifen 10 mg Tablet

Intervention Type DRUG

One tablet of Tamoxifen 10 mg every other day for 6 months

Low dose tamoxifen + Intermittent Caloric Restriction

Tamoxifen 10 mg (1 tablet) every other day for 6 months + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)

Group Type ACTIVE_COMPARATOR

Tamoxifen 10 mg Tablet

Intervention Type DRUG

One tablet of Tamoxifen 10 mg every other day for 6 months

Intermittent caloric restriction

Intervention Type OTHER

"5:2 diet": 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)

Lifestyle intervention

Step counter device

Group Type PLACEBO_COMPARATOR

Step counter Device

Intervention Type BEHAVIORAL

Participants will receive personal advice on healthy lifestyle and a step counter

Lifestyle Intervention + Intermittent Caloric Restriction

Step counter device + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)

Group Type ACTIVE_COMPARATOR

Intermittent caloric restriction

Intervention Type OTHER

"5:2 diet": 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)

Step counter Device

Intervention Type BEHAVIORAL

Participants will receive personal advice on healthy lifestyle and a step counter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tamoxifen 10 mg Tablet

One tablet of Tamoxifen 10 mg every other day for 6 months

Intervention Type DRUG

Intermittent caloric restriction

"5:2 diet": 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)

Intervention Type OTHER

Step counter Device

Participants will receive personal advice on healthy lifestyle and a step counter

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Low dose tamoxifen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women between 18 and 70 years old;
2. Healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or

\> 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models, or

with previous diagnosis of intraepithelial neoplasia (surgery for ADH, LCIS, ER positive DCIS) within the last 3 years;
3. Ability to understand and the willingness to sign a written informed consent document;
4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1;

5a. For high-risk strata: A negative mammogram or any radiological image based on age and center protocol screening within 6 months before baseline visit;

5b. For IEN Strata: A negative mammogram within 12 months before baseline visit;

6\. A negative transvaginal ultrasound within 6 months before baseline visit.

Exclusion Criteria

1. Diagnosis of ER-negative (\<10%) DCIS, or history of invasive breast cancer;
2. Previous treatment with SERMs or any other hormonal treatment for breast neoplasms;
3. BMI \< 18.5 Kg/m2 and/or Malnutrition Universal Screening Tool (MUST) score ≥2 and/or any current or past eating disorders;
4. Any diagnosis of invasive neoplasia, except non-melanoma skin cancer, in the previous 5 years;
5. Any tamoxifen contraindications (abnormal liver function, previous ischemic heart disease, endometrial disorder, previous deep venous thrombosis, history of pulmonary embolus, current or suspected glaucoma, retinopathy and cataract);
6. Current use of warfarin or other anticoagulant drugs
7. Bilateral mastectomy;
8. Pregnancy or desire to become pregnant in the subsequent 9 months after treatment cessation;
9. Diabetes or any other clinical condition that at the investigator's discretion contraindicates the proposed intervention.
10. No hormonal contraception is allowed during study intervention. Non-hormonal methods will be advised for women of childbearing potential (WOCBP)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes